Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The study is designed to compare the clinical benefit following treatment with aromatase
inhibitor in combination with metronomic capecitabine versus aromatase inhibitor alone in
women with hormone receptor-positive, Her2-negative advanced breast cancer who have not
received prior systemic anti-cancer therapies for their advanced/metastatic disease.